Steven R. Verdooner, NeuroVision (IMAGE)

Public Relations Pacific LLC

Steven R. Verdooner, NeuroVision

Caption

"In terms of emotional toll and financial cost, Alzheimer's disease is one of the greatest medical challenges of our time. As potential therapies are developed, it is critical that at-risk patients are identified early, before symptoms are seen, at a time when treatments have the potential to make a difference. We believe Janssen's support and participation will further validate the NeuroVision technology for detection and measurement of beta-amyloid plaque in Alzheimer's disease, and its progression. We are thrilled to collaborate with Janssen, and look forward to helping empower and enable new treatments," said Steven Verdooner, CEO of NeuroVision, Sacramento, California.

Credit

Neurovision Imaging LLC

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.